Asco 2025 · Posters · Cáncer Genitourinario · Lola Rodríguez Nogueira, MD Volver

A novel prognostic model to optimize the timing of docetaxel (Doc) following an androgen receptor pathway inhibitor (ARPi) in metastasic castration-resistant prostate cancer (mCRPC).

Abstract: 5063
Poster Bd #: 262
Descargar Poster

Lola Rodríguez Nogueira, MD

Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo